<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="http://hdl.handle.net/10884/1446">
    <title>DSpace Collection:</title>
    <link>http://hdl.handle.net/10884/1446</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="http://hdl.handle.net/10884/1454" />
      </rdf:Seq>
    </items>
    <dc:date>2026-04-27T17:12:05Z</dc:date>
  </channel>
  <item rdf:about="http://hdl.handle.net/10884/1454">
    <title>CSR: a catalyst for corporate contribution to global health governance? A case study from the pharmaceutical industry</title>
    <link>http://hdl.handle.net/10884/1454</link>
    <description>Title: CSR: a catalyst for corporate contribution to global health governance? A case study from the pharmaceutical industry
Authors: Monachino, Michelle; Moreira, J. Paulo
Abstract: Over the past twenty years international health and development agencies (WHO,&#xD;
1997, 2005; UN, 2002; World Bank, 2002; WEF, 2011) have gradually advocated&#xD;
towards a participation of the private for-profit sector, and especially large multinational&#xD;
corporations (MNCs), in global population health promotion and disease&#xD;
prevention. Participation has been justified in terms of the socioeconomic agency of&#xD;
corporations in a globalized world, as well as connected to the positive and negative&#xD;
social, environmental and health externalities consequent to business manufacturing,&#xD;
distribution and marketing practices.</description>
    <dc:date>2016-01-01T00:00:00Z</dc:date>
  </item>
</rdf:RDF>

